Autoimmune disorders of the neuromuscular junction

Current Opinion in Pharmacology

Volumn 9, Issue 3, 2009, Pages 336-340

  Lang, Bethan ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; ECULIZUMAB; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TRANSCRIPTION FACTOR SOX1; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; CAMPYLOBACTER ENTERITIS; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG SMALL CELL CANCER; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOKYMIA; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; PRIORITY JOURNAL; REVIEW; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; DISEASE MODELS, ANIMAL; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; ISAACS SYNDROME; LAMBERT-EATON MYASTHENIC SYNDROME; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISEASES;

EID: 65749120107     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.04.005     Document Type: Review

References (38)

1. Vincent A. Autoimmune disorders of the neuromuscular junction. Neurol India 56 (2008) 305-313
2. Giraud M., Taubert R., Vandiedonck C., Ke X., Lévi-Strauss M., Pagani F., Baralle F.E., Eymard B., Tranchant C., Gajdos P., et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 448 (2007) 934-937. Demonstration of a variant in the promoter region of CHRNA1 gene that has been associated with early onset of MG. Authors show that this variant, through IRF8 binding, significantly reduces the AIRE-regulated AChR expression in the thymus, which may alter self-tolerance thresholds.
3. Roxanis I., Micklem K., McConville J., Newsom-Davis J., and Willcox N. True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: implications for immunopathogenesis. J Neuroimmunol 125 (2002) 185-197
4. Leite M.I., Jones M., Ströbel P., Marx A., Gold R., Niks E., Verschuuren J.J., Berrih-Aknin S., Scaravilli F., Canelhas A., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells complement attack on them, and correlations with autoantibody status. Am J Pathol 171 (2007) 893-905. Demonstration of upregulation of complement components in the hyperplastic thymic epithelial cells and especially in the myoid cells in early onset MG patients. Additionally, myoid cells show a downregulation of complement regulators making myoid cells particularly susceptible to autoantibody attack.
5. Leite M.I., Ströbel P., Jones M., Micklem K., Moritz R., Gold R., Niks E.H., Berrih-Aknin S., Scaravilli F., Canelhas A., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57 (2005) 444-448
6. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., Bartoccioni E., and Evoli A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 64 (2005) 536-538
7. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., Beeson D., Willcox N., and Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131 (2008) 1940-1952. Demonstration of anti-AChR antibodies in the sera of MG patients, previously described as 'sero-negative', using a cell-based assay in which HEK cell subunits have been co-transfected with AChR and rapsyn, a protein that clusters the AChR at the NMJ.
8. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7 (2001) 365-368
9. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., and Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55 (2004) 580-584
10. Lindstrom J. Is 'seronegative' MG explained by autoantibodies to MuSK?. Neurology 62 (2004) 1920-1921
11. Kong X.C., Barzaghi P., and Ruegg M.A. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 5 (2004) 183-188
12. Jha S., Xu K., Maruta T., Oshima M., Mosier D.R., Atassi M.Z., and Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175 (2006) 107-117. Active immunisation against MuSK induces muscle weakness and reduces miniature endplate potential amplitudes in mice with evidence of morphological changes at the neuromuscular junction.
13. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., Kobayashi N., Mominoki K., Abe Y., Ueda N., and Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116 (2006) 1016-1024. Active immunisation against MuSK induces muscle weakness and demonstrates electromyographical evidence of a neuromuscular transmission defect. The antibodies act in a similar fashion to those in the human patients in various in vitro models.
14. Cole R.N., Reddel S.W., Gervásio O.L., and Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63 (2008) 782-789. IgG from anti-MuSK patients causes weakness and neuromuscular junction morphological abnormalities after injection into mice. A nice study but with limited evidence of the electrophysiological consequences of the antibodies.
15. Maddison P., Newsom-Davis J., Mills K.R., and Souhami R.L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353 (1999) 117-118
16. Wirtz P.W., Lang B., Graus F., van den Maagdenberg A.M., Saiz A., de Koning Gans P.A., Twijnstra A., and Verschuuren J.J. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 164 (2005) 161-165
17. Wirtz P.W., van Dijk J.G., van Doorn P.A., van Engelen B.G., van der Kooi A.J., Kuks J.B., Twijnstra A., de Visser M., de Visser L.H., Wokke J.H., et al. HLA and smoking in prediction and prognosis of small cell lung carcinoma in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 159 (2005) 230-237
18. Wirtz P.W., Wintzen A.R., and Verschuuren J.J. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 32 (2005) 226-229
19. Titulaer M.J., Wirtz P.W., Willems L.N., van Kralingen K.W., Smitt P.A., and Verschuuren J.J. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26 (2008) 4276-4281
20. Graus F., Vincent A., Pozo-Rosich P., Sabater L., Saiz A., Lang B., and Dalmau J. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 165 (2005) 166-171
21. Sabater L., Titulaer M., Saiz A., Verschuuren J., Gure A.O., and Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70 (2008) 924-928. The presence of antibodies to SOX-1 in the sera of patients with LEMS may aid the search for an underlying carcinoma.
22. Pellkofer H.L., Armbruster L., Krumbholz M., Titulaer M.J., Verschuuren J.J., Schumm F., and Voltz R. Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 204 (2008) 136-139
23. Hart I.K., Maddison P., Newsom-Davis J., Vincent A., and Mills K.R. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 (2002) 887-895
24. Vincent A., Buckley C., Schott J.M., Baker I., Dewar B.K., Detert N., Clover L., Parkinson A., Bien C.G., Omer S., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 (2004) 701-712
25. Kleopa K.A., Elman L.B., Lang B., Vincent A., and Scherer S.S. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 129 (2006) 1570-1584. Antibodies to various subtypes of the Shaker-type (Kv1) channels may be associated with different clinical phenotypes in patients with NMT, LE and Morvan's syndrome.
26. Turner M.R., Madkhana A., Ebers G.C., Clover L., Vincent A., McGavin G., Sarrigiannis P., Kennett R., and Warrell D.A. Wasp sting induced autoimmune neuromyotonia. JNNP 77 (2006) 704-705
27. Willison H.J. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 10 (2005) 94-112
28. Kusunoki S., Kaida K., and Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research. BBA 1780 (2008) 41-44. The presence of antibodies to conformational epitopes formed by two gangliosides (ganglioside complexes) is predictive of the clinical phenotype in patients with GBS.
29. Kaida K., Sonoo M., Ogawa G., Kamakura K., Ueda-Sada M., Arita M., Motoyoshi K., and Kusunoki S. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barré syndrome. Neurology 71 (2008) 1683-1690
30. Kaida K., Kamakura K., Ogawa G., Ueda M., Arita M., Motoyoshi K., Arita M., and Kusunoki S. GD1b-specific antibody induces ataxia in Guillain-Barré syndrome. Neurology 71 (2008) 196-201
31. Kanzaki M., Kaida K., Ueda M., Morita D., Hirakawa M., Motoyoshi K., Kamakura K., and Kusunoki S. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barré syndromes. JNNP 79 (2008) 1148-1152
32. Jacobs B.C., Koga M., van Rijs W., Geleijns K., van Doorn P.A., Willison H.J., and Yuki N. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol 194 (2008) 181-190
33. Skeie G.O., Apostolski S., Evoli A., Gilhus N.E., Hart I.K., Harms L., Hilton-Jones D., Melms A., Verschuuren J., and Horge H.W. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 13 (2006) 691-699. Consensus guidelines for the treatment of autoimmune disorders of the peripheral nervous system.
34. Dalakas M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 4 (2008) 557-567
35. Illa I., Diaz-Manera J., Rojas-Garcia R., Pradas J., Rey A., Blesa R., Juarez C., and Gallardo E. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 201-202 (2008) 90-94
36. Halstead S.K., Zitman F.M., Humphreys P.D., Greenshields K., Verschuuren J.J., Jacobs B.C., Rother R.P., Plomp J.J., and Willison H.J. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131 (2008) 1197-1208
37. Zhou Y., Gong B., Lin F., Rother R.P., Medof M.E., and Kaminski H.J. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179 (2007) 8562-8567. Clinical weakness can be alleviated in a rat model of experimental autoimmune MG by pre-treatment with antibodies to complement component C5. The experiment raises the possibility of targeting complement activation in the treatment of MG.
38. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 (2007) 1554-1557. IgG4 is an anti-inflammatory subclass of IgG that has the ability to exchange Fab arms; after such an exchange it can become functionally monovalent. Using a passive transfer monkey model of MG, the authors demonstrated that IgG4 protects the animal from experimental autoimmune MG and hence IgG4 may be useful in immunomodulatory therapy.